two chemotherapeutic regimens were compared in 102 patients with metastatic breast carcinoma , randomized to either doxorubicin-cyclophosphamide ( dc ) or cyclophosphamide-methotrexate-5-fluorouracil-vincristine-prednisone ( cmfvp ) .
C0025677
methotrexate
C0055987
cmfvp